REGN7999 + Placebo
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Transfusion Dependent Beta-Thalassemia (NTDT)
Conditions
Non-Transfusion Dependent Beta-Thalassemia (NTDT)
Trial Timeline
Sep 30, 2024 → Jan 24, 2028
NCT ID
NCT06421636About REGN7999 + Placebo
REGN7999 + Placebo is a phase 2 stage product being developed by Regeneron Pharmaceuticals for Non-Transfusion Dependent Beta-Thalassemia (NTDT). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06421636. Target conditions include Non-Transfusion Dependent Beta-Thalassemia (NTDT).
What happened to similar drugs?
1 of 2 similar drugs in Non-Transfusion Dependent Beta-Thalassemia (NTDT) were approved
Approved (1) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06421636 | Phase 2 | Recruiting |
| NCT05481333 | Phase 1 | Completed |
Competing Products
5 competing products in Non-Transfusion Dependent Beta-Thalassemia (NTDT)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| deferasirox + placebo | Novartis | Phase 2 | 35 |
| deferasirox | Novartis | Approved | 43 |
| Placebo Matching Mitapivat + Mitapivat | Agios Pharmaceuticals | Phase 3 | 38 |
| SLN124 + Placebo | Silence Therapeutics | Phase 1 | 19 |
| SLN124 is a GalNAc conjugated double stranded fully modified siRNA. Sodium chloride 0.9% w/v is used as Placebo | Silence Therapeutics | Phase 1 | 11 |